CN110133300B - 疾病样品分析装置、分析系统及分析方法 - Google Patents

疾病样品分析装置、分析系统及分析方法 Download PDF

Info

Publication number
CN110133300B
CN110133300B CN201910586450.6A CN201910586450A CN110133300B CN 110133300 B CN110133300 B CN 110133300B CN 201910586450 A CN201910586450 A CN 201910586450A CN 110133300 B CN110133300 B CN 110133300B
Authority
CN
China
Prior art keywords
mice
disease
amino acid
urine
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201910586450.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110133300A (zh
Inventor
浜濑健司
东條洋介
三田真史
水本智惠子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirror Co ltd
Original Assignee
Mirror Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirror Co ltd filed Critical Mirror Co ltd
Publication of CN110133300A publication Critical patent/CN110133300A/zh
Application granted granted Critical
Publication of CN110133300B publication Critical patent/CN110133300B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/89—Inverse chromatography
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8818—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8877—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201910586450.6A 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法 Expired - Fee Related CN110133300B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012061305 2012-03-18
JP2012-061305 2012-03-18
CN201380019921.6A CN104246497B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380019921.6A Division CN104246497B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法

Publications (2)

Publication Number Publication Date
CN110133300A CN110133300A (zh) 2019-08-16
CN110133300B true CN110133300B (zh) 2022-02-25

Family

ID=49222264

Family Applications (11)

Application Number Title Priority Date Filing Date
CN201910586450.6A Expired - Fee Related CN110133300B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910585588.4A Pending CN110133297A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910591893.4A Active CN110133301B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201710913596.8A Expired - Fee Related CN107449923B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201380019921.6A Expired - Fee Related CN104246497B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910585649.7A Pending CN110133298A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910591882.6A Active CN110161256B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910585530.XA Active CN110133296B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN202210524153.0A Pending CN114966050A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910586159.9A Pending CN110133299A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910585495.1A Pending CN110133295A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法

Family Applications After (10)

Application Number Title Priority Date Filing Date
CN201910585588.4A Pending CN110133297A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910591893.4A Active CN110133301B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201710913596.8A Expired - Fee Related CN107449923B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201380019921.6A Expired - Fee Related CN104246497B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910585649.7A Pending CN110133298A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910591882.6A Active CN110161256B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910585530.XA Active CN110133296B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN202210524153.0A Pending CN114966050A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910586159.9A Pending CN110133299A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910585495.1A Pending CN110133295A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法

Country Status (7)

Country Link
US (2) US20150079623A1 (cg-RX-API-DMAC7.html)
EP (3) EP3663758A1 (cg-RX-API-DMAC7.html)
JP (3) JP6037388B2 (cg-RX-API-DMAC7.html)
CN (11) CN110133300B (cg-RX-API-DMAC7.html)
IN (1) IN2014MN02060A (cg-RX-API-DMAC7.html)
TW (2) TWI664425B (cg-RX-API-DMAC7.html)
WO (1) WO2013140785A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10393749B2 (en) 2013-12-11 2019-08-27 Shiseido Company, Ltd. Marker for early diagnosis of kidney failure
CN107683414A (zh) * 2015-06-10 2018-02-09 国立大学法人金泽大学 肾病的病态生物标志物
CN105154487B (zh) * 2015-10-10 2019-03-05 中国科学院南海海洋研究所 氨基转移酶和异构酶在催化形成L-allo-Ile中的应用
JP7123329B2 (ja) * 2016-05-17 2022-08-23 国立大学法人大阪大学 腎臓病の予後予測方法及びシステム
CN109154619A (zh) * 2016-05-17 2019-01-04 国立大学法人大阪大学 用于判定糖尿病的血液试样的分析方法及系统
JPWO2018092818A1 (ja) 2016-11-15 2019-10-17 株式会社 資生堂 多次元クロマトグラフィー分析方法及び分析システム
JPWO2018159833A1 (ja) * 2017-03-02 2020-01-16 株式会社ニコン 細胞の判別方法、がんの検査方法、計測装置、がんの検査装置および検査プログラム
US20200002322A1 (en) 2017-03-03 2020-01-02 Shiseido Company, Ltd. Novel compound, fluorescence derivatization reagent including said novel compound, method for optically resolving optical isomer of amino acid in which said novel compound is used, and fluorescence derivatized amino acid
CN112469404A (zh) * 2018-06-07 2021-03-09 国立大学法人金泽大学 肾损伤的预防或治疗用的药物组合物
JP7366428B2 (ja) * 2018-08-27 2023-10-23 Kagami株式会社 乾癬を判定するための皮膚試料の分析方法及びシステム
JP6868878B2 (ja) 2018-10-17 2021-05-12 Kagami株式会社 糸球体濾過能力の決定方法
US12480954B2 (en) 2019-03-22 2025-11-25 Kagami Inc. Method for assisting evaluation of condition of kidneys, system for evaluating condition of kidneys, and program for evaluating condition of kidneys
US20220170945A1 (en) * 2019-03-22 2022-06-02 Kagami Inc. Method for assisting evaluation of renal pathological conditions, system for evaluating renal pathological conditions and program for evaluating renal pathological conditions
JP7434678B2 (ja) * 2019-05-20 2024-02-21 花王株式会社 認知症又はそのリスクの検査方法
EP4083628B1 (en) 2019-12-27 2026-03-11 Kagami Inc. Method and system for estimating renal function
CN121324515A (zh) * 2020-09-16 2026-01-13 上海市皮肤病医院 基于代谢组学的泛发性脓疱型银屑病诊断标志物及其应用
CN111899883B (zh) * 2020-09-29 2020-12-15 平安科技（深圳）有限公司 少样本或零样本的疾病预测设备、方法、装置及存储介质
JP7600016B2 (ja) * 2021-03-30 2024-12-16 花王株式会社 高次脳機能の測定方法
JPWO2023033178A1 (cg-RX-API-DMAC7.html) * 2021-09-03 2023-03-09
JP2026023560A (ja) * 2024-07-31 2026-02-13 Kagami株式会社 神経膠腫に関する情報を提供する方法及びシステム

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948764A (en) * 1995-03-09 1999-09-07 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis utilizing peptide analogues of human myelin basic protein
CN1541278A (zh) * 2001-08-14 2004-10-27 ����ɭ�������ƹɷ����޹�˾ 新的神经毒性的分子靶
CN1649898A (zh) * 2002-04-10 2005-08-03 维克斯咨询公司 新型肽及其的治疗中的应用
CN101636384A (zh) * 2007-01-18 2010-01-27 塞普拉柯公司 D-氨基酸氧化酶的抑制剂

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4290893A (en) * 1979-05-08 1981-09-22 Yeda Research & Development Co. Ltd. Separation of amino acids by liquid chromatography using chiral eluants
CA2030212A1 (en) * 1989-11-22 1991-05-23 Judson V. Edwards Peptides
US5374651A (en) * 1991-09-27 1994-12-20 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives
JPH0975078A (ja) * 1995-09-13 1997-03-25 Ikeda Shokken Kk 耐熱性ｄ−アミノ酸オキシダーゼ、その製造法および微生物
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
EP0882736A1 (en) * 1997-06-02 1998-12-09 Laboratoire Theramex S.A. LH-RH peptide analogues, their uses and pharmaceutical compositions containing them
IL140069A0 (en) * 1998-06-11 2002-02-10 Fox Chase Cancer Ct A method for assessing a diabetic's risk of experiencing a diabetes-associated pathologic condition
ES2459745T3 (es) * 1999-05-14 2014-05-12 Brandeis University Detección basada en aptámero
US6479063B2 (en) * 1999-12-27 2002-11-12 Kenneth Weisman Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
US7223558B2 (en) * 2001-07-11 2007-05-29 Bristol-Myers Squibb Company Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
AU2003217783A1 (en) * 2002-02-27 2003-09-09 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
US20070298041A1 (en) * 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
WO2004005935A1 (ja) * 2002-07-04 2004-01-15 Mitsubishi Pharma Corporation 統合失調症の検査、診断方法
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
GB0223424D0 (en) * 2002-10-09 2002-11-13 Imp College Innovations Ltd Disease-associated gene
JP4581994B2 (ja) * 2002-12-09 2010-11-17 味の素株式会社 生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、および、記録媒体
WO2004063221A1 (ja) * 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited メタスチン誘導体およびその用途
AU2003900777A0 (en) * 2003-02-21 2003-03-13 Medvet Science Pty. Ltd. A method of diagnosis and treatment
CA2518703A1 (en) * 2003-03-10 2004-09-23 Sionex Corporation Systems for differential ion mobility analysis
CA2521221A1 (en) * 2003-04-02 2004-10-14 Genix Therapeutics, Inc. Method for the treatment of prostate cancer
JP4291628B2 (ja) 2003-06-12 2009-07-08 株式会社資生堂 液体クロマトグラフ装置及び試料に含まれる光学異性体の分析方法
CN1557823A (zh) * 2004-02-12 2004-12-29 窦德献 L-或d-氨基酸合铂配位体、制备方法及其用途
ATE491043T1 (de) * 2004-04-09 2010-12-15 Us Gov Health & Human Serv Diagnosegerät zur diagnose gutartiger gegenüber bösartigen schilddrüsenläsionen
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
GB0417887D0 (en) * 2004-08-11 2004-09-15 Ares Trading Sa Protein
KR101286833B1 (ko) * 2005-03-18 2013-07-17 가부시키가이샤 시세이도 편평상피세포암 관련 항원을 지표로 하는 피부 성상의 평가방법
CN101189243A (zh) * 2005-04-06 2008-05-28 阿斯利康(瑞典)有限公司 取代的杂环及其作为chk1、pdk1和pak抑制剂的应用
JP2007077104A (ja) * 2005-09-16 2007-03-29 Shiseido Co Ltd 血管内皮増殖因子阻害剤
ES2392629T3 (es) * 2006-03-02 2012-12-12 Perkinelmer Health Sciences, Inc. Métodos de distinción de isómeros mediante espectrometría de masas
US20070258899A1 (en) * 2006-03-31 2007-11-08 Karyon-Ctt Ltd Diagnostic and therapeutic agents
JP5005955B2 (ja) * 2006-05-24 2012-08-22 田辺三菱製薬株式会社 被験物質の脂質代謝異常症誘発可能性を予測する方法
WO2008005469A2 (en) * 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
BRPI0716190A2 (pt) * 2006-09-06 2013-11-12 Aeterna Zentaris Gmbh Conjugados de disorazóis e seus derivados com móleculas de ligação celular, derivados de disorazol, processos para fabricação e uso dos mesmos
EP1900742A1 (en) * 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
US20090075284A1 (en) * 2006-09-19 2009-03-19 The Regents Of The University Of Michigan Metabolomic profiling of prostate cancer
JP2010518812A (ja) * 2007-02-12 2010-06-03 アンスロジェネシス コーポレーション 接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにｃｄ３４＋、ｃｄ４５−胎盤幹細胞の濃縮細胞集団
US8034780B2 (en) * 2007-07-16 2011-10-11 Mcphail Kerry Leigh Isolation, purification, and structure elucidation of the antiproliferative compound coibamide A
EP2239576A1 (en) * 2008-01-17 2010-10-13 Toray Industries, Inc. Composition and method for diagnosis or detection of gastric cancer
JP2009184981A (ja) * 2008-02-07 2009-08-20 Shiseido Co Ltd 抗ｄ−アミノ酸モノクローナル抗体及び、抗ｄ−アミノ酸モノクローナル抗体を用いたｄ−アミノ酸の免疫学的分析方法
CL2009001156A1 (es) * 2008-05-14 2010-08-27 Canbas Co Ltd Acetato de un peptido de 12 aminoacidos; metodo de preparacion; composicion farmaceutica y agente que lo contiene, solo o conjuntamente con un principio activo que dana el acido nucleico; util para el tratamiento o profilaxis de trastornos proliferativos celulares.
WO2009143489A2 (en) * 2008-05-22 2009-11-26 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
US20110311650A1 (en) * 2008-07-07 2011-12-22 Thomas Wang Multiplexed biomarkers of insulin resistance
JP2010038796A (ja) * 2008-08-06 2010-02-18 Human Metabolome Technologies Inc 疾患マーカー、および、疾患マーカーの測定方法
WO2010024091A1 (ja) * 2008-08-26 2010-03-04 国立大学法人九州大学 Ｄａｏ１－／－マウスを活用したＤ－アミノ酸関連疾患の評価・スクリーニング方法
US8722343B2 (en) * 2008-11-21 2014-05-13 Carla Perego Methods and compositions for the diagnosis and treatment of diabetes
ES2799327T3 (es) * 2009-05-05 2020-12-16 Infandx Ag Método para diagnosticar asfixia
CN101619092B (zh) * 2009-08-06 2012-08-15 中国人民解放军第三军医大学第二附属医院 肿瘤抗原trag-3模拟表位肽及其应用
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
JP2011247869A (ja) * 2010-04-27 2011-12-08 Kobe Univ メタボローム解析手法を用いた特定疾患の検査方法
CN102079771B (zh) * 2010-12-10 2012-10-03 郑州大学 具有抗肿瘤活性的雌甾氨基酸酯化合物及其合成方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948764A (en) * 1995-03-09 1999-09-07 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis utilizing peptide analogues of human myelin basic protein
CN1541278A (zh) * 2001-08-14 2004-10-27 ����ɭ�������ƹɷ����޹�˾ 新的神经毒性的分子靶
CN1649898A (zh) * 2002-04-10 2005-08-03 维克斯咨询公司 新型肽及其的治疗中的应用
CN101636384A (zh) * 2007-01-18 2010-01-27 塞普拉柯公司 D-氨基酸氧化酶的抑制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Different roles of D-axnino acids in immune phenomena;Michael Sela等;《The FASEB Journal》;19970531;第11卷;第449-456页 *
Free D-Amino Acids in Human Cerebrospinal Fluid of Alzheimer Disease, Multiple Sclerosis, and Healthy Control Subjects;George H. Fisher等;《Molecular and Chemical Neuropathology》;19941231;第23卷;第115-124页 *

Also Published As

Publication number Publication date
EP3795997B1 (en) 2022-08-24
IN2014MN02060A (cg-RX-API-DMAC7.html) 2015-08-21
CN114966050A (zh) 2022-08-30
CN110161256A (zh) 2019-08-23
CN110133301A (zh) 2019-08-16
CN110133298A (zh) 2019-08-16
CN110133299A (zh) 2019-08-16
TW201736851A (zh) 2017-10-16
CN107449923A (zh) 2017-12-08
JP2017223711A (ja) 2017-12-21
JP6391787B2 (ja) 2018-09-19
CN104246497B (zh) 2017-10-13
CN110133297A (zh) 2019-08-16
EP3663758A1 (en) 2020-06-10
EP2829877A1 (en) 2015-01-28
EP2829877A4 (en) 2015-12-09
CN110133301B (zh) 2022-03-22
EP3795997A1 (en) 2021-03-24
JP6037388B2 (ja) 2016-12-07
WO2013140785A1 (ja) 2013-09-26
TWI664425B (zh) 2019-07-01
CN110161256B (zh) 2022-03-25
CN104246497A (zh) 2014-12-24
JP6214016B2 (ja) 2017-10-18
CN110133296B (zh) 2022-03-25
TW201344194A (zh) 2013-11-01
JP2013224929A (ja) 2013-10-31
US20150079623A1 (en) 2015-03-19
CN107449923B (zh) 2020-07-24
TWI615614B (zh) 2018-02-21
CN110133295A (zh) 2019-08-16
CN110133296A (zh) 2019-08-16
US20190025320A1 (en) 2019-01-24
CN110133300A (zh) 2019-08-16
JP2017015741A (ja) 2017-01-19
EP2829877B1 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
CN110133301B (zh) 疾病样品分析装置、分析系统及分析方法
JP2013224929A5 (cg-RX-API-DMAC7.html)
US20190339281A1 (en) Marker for early diagnosis of kidney failure
US11099191B2 (en) Kidney disease prognosis prediction method and system
CN109154619A (zh) 用于判定糖尿病的血液试样的分析方法及系统
JP2025013689A (ja) 猫の腎機能障害の検査方法
Zhou et al. Irisin and volume overload are associated with protein energy wasting in peritoneal dialysis patients
WO2020196436A1 (ja) 腎病態の評価を補助する方法、腎病態の評価システム及び腎病態の評価プログラム

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200713

Address after: Osaka Japan

Applicant after: Mirror Co.,Ltd.

Address before: Tokyo, Japan

Applicant before: SHISEIDO Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220225